Alvotech (ALVO)

Jun 6, 2025, 8:30 AM EDT - 20 hours ago

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 20 hours ago

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Jun 5, 2025, 1:56 PM EDT - 1 day ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

MRK RDY

Jun 4, 2025, 10:29 PM EDT - 2 days ago

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Jun 4, 2025, 11:32 AM EDT - 2 days ago

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Jun 4, 2025, 7:45 AM EDT - 2 days ago

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Jun 2, 2025, 9:15 AM EDT - 4 days ago

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

May 28, 2025, 6:15 AM EDT - 9 days ago

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

May 26, 2025, 2:06 PM EDT - 11 days ago

Alvotech Annual General Meeting to be held June 25, 2025

May 23, 2025, 12:11 PM EDT - 14 days ago

Transactions of Managers and Closely Associated Persons

May 19, 2025, 3:15 AM EDT - 19 days ago

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 19, 2025, 2:30 AM EDT - 19 days ago

Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

May 16, 2025, 1:52 PM EDT - 21 days ago

Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm

May 11, 2025, 1:08 AM EDT - 27 days ago

Alvotech (ALVO) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:30 AM EDT - 4 weeks ago

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 7, 2025, 4:45 PM EDT - 4 weeks ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 4:45 PM EDT - 4 weeks ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 5:00 AM EDT - 4 weeks ago

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

May 2, 2025, 8:30 AM EDT - 5 weeks ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

May 2, 2025, 8:30 AM EDT - 5 weeks ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Apr 30, 2025, 4:39 PM EDT - 5 weeks ago

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

Mar 28, 2025, 5:01 PM EDT - 2 months ago

This Is a Test From GlobeNewswire

CMPS

Mar 27, 2025, 12:09 PM EDT - 2 months ago

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:30 AM EDT - 2 months ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Mar 26, 2025, 6:36 PM EDT - 2 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 6:34 PM EDT - 2 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 4:30 AM EDT - 2 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 26, 2025, 4:30 AM EDT - 2 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 20, 2025, 3:00 AM EDT - 2 months ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 20, 2025, 3:00 AM EDT - 2 months ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 7, 2025, 9:00 AM EST - 3 months ago

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Feb 24, 2025, 8:00 AM EST - 3 months ago

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Feb 21, 2025, 6:44 AM EST - 3 months ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

JNJ TEVA

Feb 21, 2025, 6:00 AM EST - 3 months ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Feb 18, 2025, 11:30 AM EST - 3 months ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

TEVA

Feb 18, 2025, 6:00 AM EST - 3 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Jan 27, 2025, 6:00 AM EST - 4 months ago

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Dec 23, 2024, 4:00 AM EST - 5 months ago

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

Nov 21, 2024, 2:02 AM EST - 7 months ago

Alvotech's Position In The Coming Biosimilar Gold Rush

Nov 15, 2024, 8:00 AM EST - 7 months ago

Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors

Nov 14, 2024, 1:59 PM EST - 7 months ago

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:00 AM EST - 7 months ago

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024

Nov 4, 2024, 7:00 AM EST - 7 months ago

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)

Oct 25, 2024, 8:00 AM EDT - 8 months ago

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Oct 10, 2024, 5:01 AM EDT - 8 months ago

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Oct 2, 2024, 12:08 PM EDT - 8 months ago

Alvotech (ALVO) Shares Up 3.77% on Oct 2

Sep 25, 2024, 5:01 AM EDT - 9 months ago

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Aug 26, 2024, 9:15 AM EDT - 10 months ago

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 8:00 AM EDT - 10 months ago

Alvotech: Steady Progress Offers A Good Chance Of Upside

Aug 16, 2024, 10:27 AM EDT - 10 months ago

Alvotech (ALVO) Q2 2024 Earnings Call Transcript